161 related articles for article (PubMed ID: 37625815)
1. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Berenguer-Ruiz S; Aparicio-Domínguez M; Herranz-Pinto P; Ruíz-Villaverde R; López-Ferrer A; Santos-Juanes J; Rodríguez Fernández-Freire L; Hospital-Gil M; Arias-Santiago S; Carretero-Hernández G; Mateu-Puchades A; Ferran M; Del Alcázar E; Santos-Alarcón S; Garcia-Latasa de Aranibar FJ; Belinchón-Romero I; González-Cantero Á; Ruíz-Genao D; Eiris-Salvado N; Rocamora-Durán V; Rivera-Diaz R; de la Cueva P; Daudén E; Salgado-Boquete L; Llamas-Velasco M;
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2517-2525. PubMed ID: 37625815
[TBL] [Abstract][Full Text] [Related]
2. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
Narcisi A; Valenti M; Gargiulo L; Ibba L; Amoruso F; Argenziano G; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Franchi C; Girolomoni G; Guarneri C; Loconsole F; Sampogna F; Travaglini M; Malagoli P; Costanzo A
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):93-103. PubMed ID: 36156312
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis.
Di Brizzi EV; Buononato D; Benvenuto P; Argenziano G; De Pasquale R; Fiorella CS; Giofrè C; Musumeci ML; Palazzo G; Zichichi L; Balato A
Dermatol Pract Concept; 2023 Oct; 13(4):. PubMed ID: 37992389
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study.
Heim J; Vasquez JG; Schenkel B; Bhatia N
J Drugs Dermatol; 2023 Aug; 22(8):754-760. PubMed ID: 37556515
[TBL] [Abstract][Full Text] [Related]
5. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients.
Drerup KA; Seemann C; Gerdes S; Mrowietz U
Dermatology; 2022; 238(4):615-619. PubMed ID: 34775387
[TBL] [Abstract][Full Text] [Related]
6. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
[TBL] [Abstract][Full Text] [Related]
7. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
Caldarola G; Galluzzo M; Bernardini N; Calabrese L; Grimaldi M; Moretta G; Pagnanelli G; Shumak RG; Talamonti M; Tofani L; Pallotta S; Peris K; Potenza C; De Simone C; Campione E
Dermatol Ther; 2022 Jun; 35(6):e15488. PubMed ID: 35384168
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
[TBL] [Abstract][Full Text] [Related]
9. A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients.
Campione E; Lambiase S; Gaeta Shumak R; Galluzzo M; Lanna C; Costanza G; Borselli C; Artosi F; Cosio T; Tofani L; Dattola A; Di Daniele F; Bianchi L
Pharmaceuticals (Basel); 2023 Mar; 16(4):. PubMed ID: 37111283
[TBL] [Abstract][Full Text] [Related]
10. Tildrakizumab in Complex Psoriatic Patients: An Experience in Emilia-Romagna (Italy).
Bardazzi F; Viviani F; Piraccini BM; Lasagni C; Bigi L; Manfredini M; Pongetti L; Di Lernia V; Corazza M; Pepe F
J Cutan Med Surg; 2023; 27(2):126-132. PubMed ID: 36995351
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis patients' characteristics associated with high PASI response to tildrakizumab: an international dual center study.
Burlando M; Maul JT; Salvi I; Simic D; Cozzani E; Ak M; Birkenmaier I; Parodi A
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6772-6776. PubMed ID: 36196725
[TBL] [Abstract][Full Text] [Related]
12. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
13. 52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience.
Melgosa Ramos FJ; Mateu Puchades A; Matáix-Díaz J; Schneller-Pavelescu L; Belinchón-Romero I; Santos Alarcón S
Actas Dermosifiliogr; 2024 Mar; ():. PubMed ID: 38556201
[TBL] [Abstract][Full Text] [Related]
14. 52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience.
Melgosa Ramos FJ; Mateu Puchades A; Matáix-Díaz J; Schneller-Pavelescu L; Belinchón-Romero I; Santos Alarcón S
Actas Dermosifiliogr; 2024 May; ():. PubMed ID: 38777224
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
[TBL] [Abstract][Full Text] [Related]
16. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
[TBL] [Abstract][Full Text] [Related]
17. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis.
Elgaard CDB; Iversen L; Hjuler KF
J Dermatolog Treat; 2023 Dec; 34(1):2133531. PubMed ID: 36200762
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
[TBL] [Abstract][Full Text] [Related]
19. Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis.
Bagel J; Novak K; Nelson E
J Drugs Dermatol; 2023 Aug; 22(8):766-772. PubMed ID: 37556520
[TBL] [Abstract][Full Text] [Related]
20. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
